IceCure granted Chinese patent for cryogenic connector
No actual results were disclosed, so there is no beat, miss, or in-line comparison with the prior FY2026 guidance midpoint. China’s National Intellectual Property Administration granted IceCure a new patent covering a connector used in its cryogenic technology platform, while IceCure reported an intellectual property portfolio of 42 patents across the United States, Europe, Great Britain, China, and Japan. The release also notes that China’s National Medical Products Administration approved ProSense and its asso...
Key takeaways
China patent: CNIPA granted IceCure a patent covering a connector used in the company’s cryogenic technology platform.
Portfolio size: IceCure reported 42 patents across the United States, Europe, Great Britain, China, and Japan.
China authorization: China’s NMPA approved ProSense and its associated cryoprobes for marketing in China in September 2026.
Patent scope: IceCure said the patent grant expands protection for proprietary cryogenic technologies in an international market.
Financial disclosure: The filing provides no actual financial results, guidance, guidance updates, transaction terms, or customer-concentration data.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow ICCM in real time
Get material earnings, filing, IR, and earnings-call alerts by email.